Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The founder of medical device company Alida notes that marketing her product for sexual wellness could boost short-term sales but would deter a potential acquisition by a traditional medical device company. This reveals a critical choice: founders must align today's marketing with their long-term exit strategy.
Related Insights
Preparing a company for acquisition can lead founders to make short-term decisions that please the acquirer but undermine the brand's core agility, setting it up for failure post-sale. The focus shifts from longevity to a transaction.
Rabois introduces a nuanced framework beyond just product-market fit. He argues that exceptional marketing can create a temporary illusion of success, but this "marketing fit" will eventually collapse if the underlying product value isn't there to retain users.
Founders must consider their sales motion (e.g., PLG vs. enterprise sales-led) when designing the product. A product built for one motion won't sell effectively in another, potentially forcing a costly redesign. This concept extends "product-market fit" to "product-market-sales fit."
The "build it and they will come" mindset is a trap. Founders should treat marketing and brand-building not as a later-stage activity to be "turned on," but as a core muscle to be developed in parallel with the product from day one.
A successful exit is a highly choreographed dance, not an abrupt decision. Founders should spend years building relationships with line-of-business leaders—not just Corp Dev—at potential acquiring companies. The goal is to 'incept' the idea of an acquisition long before it's needed.
Initial lowball acquisition offers can feel defeating, forcing a founder to abandon the exit dream. This forces a necessary shift to building a sustainable, long-term business. This new focus, ironically, is what makes the company far more attractive to acquirers in the future.
Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.
Success in startups requires nuanced thinking, not absolute rules. For instance, product-market fit isn't a simple 'yes' or 'no' checkbox; it exists on a spectrum. Learning to see these shades of gray in funding, marketing, and product strategy is a hallmark of a mature founder.
When interviewing, ask founders about their perspective on long-term brand investments versus short-term pipeline goals. Their answer reveals if they understand marketing's true value beyond being a sales support function, indicating the strategic role you'll be allowed to play.
To achieve a high-value acquisition, biotechs must first build a credible strategy to succeed independently, creating a position of strength. Concurrently, leaders should keep multiple potential suitors proactively informed on all business aspects—not just clinical data—to facilitate a competitive bidding process when the time comes.
